HLA-B*5801: a genetic susceptibility to allopurinol-induced DRESS

• 1 Lyell McEwin Hospital, Adelaide, SA
• 2 School of Medicine, University of Adelaide, Adelaide, SA

---

• 1. Hoffman R, Benz EJ, Silberstein LE, et al. Haematology: basic principles and practice. 6th ed. Philadelphia: Elsevier Saunders, 2013.
• 2. Lee MH, Stocker SL, Anderson J, et al. Initiating allopurinol therapy: do we need to know the patient’s HLA status? Intern Med J 2011; 42: 411-416.
• 3. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-4139.
• 4. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93: 153-158.
• 5. Australian Bureau of Statistics. 2011 Census of Population and Housing: basic community profile: Australia. Canberra: ABS, 2013. http://www.censusdata.abs.gov.au/CensusOutput/copsub.NSF/All%20docs%20by%20catNo/2011∼Community%20Profile∼0/$File/BCP_0.zip?OpenElement (accessed Sep 2015).
• 6. Khanna D, Fitzgerald J, Khanna P, et al. 2012 American College of Rheumatology Guidelines for Management of Gout Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431-1446.
• 7. Saokaew S, Tassaneeyakul W, Maenthaisong R, et al. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PLoS One 2014; 9: e94294.
• 8. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2015.
• 9. Rheumatology Expert Group. Therapeutic guidelines: rheumatology. Version 2. Melbourne: Therapeutic Guidelines Limited, 2010.
• 10. Australian Government Department of Health. Pharmaceutical Benefits Scheme [website]. http://www.pbs.gov.au (accessed Sep 2015).